DOP2018000157A - Agonista triple de receptores de glucagón/glp-1/gip - Google Patents

Agonista triple de receptores de glucagón/glp-1/gip

Info

Publication number
DOP2018000157A
DOP2018000157A DO2018000157A DO2018000157A DOP2018000157A DO P2018000157 A DOP2018000157 A DO P2018000157A DO 2018000157 A DO2018000157 A DO 2018000157A DO 2018000157 A DO2018000157 A DO 2018000157A DO P2018000157 A DOP2018000157 A DO P2018000157A
Authority
DO
Dominican Republic
Prior art keywords
glp
glucagon
gip
receivers
triple agonist
Prior art date
Application number
DO2018000157A
Other languages
English (en)
Spanish (es)
Inventor
Youb Jung Sung
Lim Oh Euh
Ki Lim Chang
Chang Kwon Se
Suk Lee Jong
Jin Park Young
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of DOP2018000157A publication Critical patent/DOP2018000157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DO2018000157A 2015-12-31 2018-06-28 Agonista triple de receptores de glucagón/glp-1/gip DOP2018000157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150191082 2015-12-31
KR20160163737 2016-12-02

Publications (1)

Publication Number Publication Date
DOP2018000157A true DOP2018000157A (es) 2018-10-15

Family

ID=59225193

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2018000157A DOP2018000157A (es) 2015-12-31 2018-06-28 Agonista triple de receptores de glucagón/glp-1/gip
DO2018000159A DOP2018000159A (es) 2015-12-31 2018-06-29 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip

Family Applications After (1)

Application Number Title Priority Date Filing Date
DO2018000159A DOP2018000159A (es) 2015-12-31 2018-06-29 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip

Country Status (33)

Country Link
US (6) US10400020B2 (enExample)
EP (3) EP3398961B1 (enExample)
JP (5) JP6712323B2 (enExample)
KR (8) KR20170080521A (enExample)
CN (6) CN116059389A (enExample)
AU (4) AU2016382394B2 (enExample)
BR (1) BR112018013530A2 (enExample)
CA (2) CA3010182A1 (enExample)
CL (6) CL2018001776A1 (enExample)
CO (2) CO2018006982A2 (enExample)
CR (2) CR20180380A (enExample)
DK (1) DK3398961T3 (enExample)
DO (2) DOP2018000157A (enExample)
EA (2) EA038524B1 (enExample)
EC (2) ECSP18053053A (enExample)
ES (1) ES2925098T3 (enExample)
HK (1) HK1258177A1 (enExample)
HR (1) HRP20220995T1 (enExample)
HU (1) HUE059737T2 (enExample)
IL (2) IL260318B2 (enExample)
MX (2) MX2018008128A (enExample)
PE (3) PE20250556A1 (enExample)
PH (2) PH12018501411B1 (enExample)
PL (1) PL3398961T3 (enExample)
PT (1) PT3398961T (enExample)
RS (1) RS63541B1 (enExample)
SA (2) SA518391891B1 (enExample)
SG (2) SG11201805573RA (enExample)
TN (2) TN2018000228A1 (enExample)
TW (4) TWI877582B (enExample)
UA (2) UA130791C2 (enExample)
WO (2) WO2017116205A1 (enExample)
ZA (2) ZA201804997B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
KR102291020B1 (ko) 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
CN122440793A (zh) 2016-06-29 2026-07-24 韩美药品株式会社 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途
EP3578204A4 (en) 2017-02-03 2021-01-06 Hanmi Pharm. Co., Ltd. CONJUGATE MADE FROM BIOACTIVE MATERIAL WITH INCREASED RESISTANCE AND USE OF IT
US11925691B2 (en) 2017-02-07 2024-03-12 Hanmi Pharm. Co., Ltd. Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
TWI810937B (zh) 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI912614B (zh) 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
WO2020130749A1 (ko) 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
KR102982428B1 (ko) 2019-02-15 2026-06-25 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
WO2020214012A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
MX2021015927A (es) * 2019-06-28 2022-04-18 Hanmi Pharm Ind Co Ltd Uso terapéutico de agonista trigonal de los receptores de glucagón, glp-1 y gip, o conjugado de los mismos para enfermedades hepáticas.
WO2021034815A1 (en) 2019-08-19 2021-02-25 Eli Lilly And Company Methods of making incretin analogs
JP7761557B2 (ja) * 2019-10-04 2025-10-28 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
KR20220100925A (ko) 2019-11-11 2022-07-18 베링거 인겔하임 인터내셔날 게엠베하 Npy2 수용체 작용제
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CN111040022B (zh) * 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
PE20221595A1 (es) * 2020-01-13 2022-10-10 Hanmi Pharm Ind Co Ltd Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
TW202203963A (zh) * 2020-04-20 2022-02-01 南韓商韓美藥品股份有限公司 用於預防或治療高血脂症之包含三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑或其接合物之組成物及其使用方法
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2021276071B2 (en) * 2020-05-22 2026-06-18 Hanmi Pharm. Co., Ltd. Liquid formulation
CN115811970A (zh) * 2020-05-22 2023-03-17 韩美药品株式会社 胰高血糖素、glp-1和gip三重激动剂的长效缀合物的液体制剂
CN118754965A (zh) 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
US20230310630A1 (en) * 2020-07-17 2023-10-05 Hanmi Pharm. Co., Ltd. Therapeutic use of combination comprising triple agonistic long-acting conjugate or triple agonist
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
JP2023537895A (ja) * 2020-08-14 2023-09-06 ハンミ ファーマシューティカル カンパニー リミテッド 三重活性体持続型結合体を有効成分として含む薬学組成物
WO2022035302A1 (ko) 2020-08-14 2022-02-17 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
JP2023543043A (ja) * 2020-09-25 2023-10-12 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の持続型結合体の多発性硬化症の治療用途
WO2022065897A1 (ko) 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도
WO2022065898A1 (ko) 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
CN116635055A (zh) * 2020-10-16 2023-08-22 韩美药品株式会社 包括gip衍生物或其长效缀合物的用于预防或治疗狼疮相关疾病的药物组合物
JP2023546384A (ja) * 2020-10-16 2023-11-02 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の呼吸器感染疾患の後遺症の治療用途
EP4230218A4 (en) * 2020-10-16 2024-11-20 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating vasculitis
CN116615254A (zh) * 2020-10-16 2023-08-18 韩美药品株式会社 对胰高血糖素、glp-1和gip受体全部具有活性的三角激动剂在治疗呼吸道感染性疾病后的后遗症中的用途
US20230381281A1 (en) * 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
CN116583533A (zh) 2020-10-16 2023-08-11 韩美药品株式会社 Gip衍生物、其长效缀合物和包括其的药物组合物
WO2022090447A1 (en) 2020-10-30 2022-05-05 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
MX2023006419A (es) * 2020-12-02 2023-08-15 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Compuestos polipéptidos modificados con lactama.
CN116635050A (zh) * 2020-12-24 2023-08-22 韩美药品株式会社 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
EP4342487A2 (en) * 2021-01-29 2024-03-27 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising gip derivative or long-acting conjugate thereof for preventing or treating pulmonary disease
CA3219647A1 (en) * 2021-05-26 2022-12-01 The United Bio-Technology (Hengqin) Co., Ltd. Multi agonists and use thereof
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
TW202313667A (zh) * 2021-07-30 2023-04-01 大陸商南京明德新藥研發有限公司 含內醯胺橋的多肽化合物
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
KR20230095665A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 약물 및 이의 용도
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023228156A1 (en) * 2022-05-27 2023-11-30 D&D Pharmatech Inc. Peptide compositions and methods of use threof
IL324886A (en) * 2022-12-23 2026-01-01 Hanmi Pharmaceutical Co Ltd Novel triple glp-1/gip/glucagon receptor agonistand a pharmaceutical composition for preventing ortreating obesity comprising the same
AU2024215381A1 (en) 2023-01-31 2025-09-18 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
EP4724472A2 (en) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
KR20250177375A (ko) * 2024-06-13 2025-12-23 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물
WO2025259064A1 (ko) * 2024-06-13 2025-12-18 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물
WO2025259063A1 (ko) * 2024-06-13 2025-12-18 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 당뇨 예방 또는 치료용 약학적 조성물
WO2025259062A1 (ko) * 2024-06-13 2025-12-18 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 신장 질환의 예방 또는 치료용 약학적 조성물
WO2026076425A1 (en) 2024-10-04 2026-04-09 Biodrive, Inc. Oral biodelivery platform
CN120189527B (zh) * 2025-05-27 2026-04-03 广州富肽生物有限公司 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5476304A (en) 1977-11-29 1979-06-18 Tokyo Printing Ink Mfg Co Ltd Ink
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
JP2002538084A (ja) * 1999-01-14 2002-11-12 アミリン・ファーマシューティカルズ，インコーポレイテッド グルカゴンを抑制する方法
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
DE60137876D1 (de) * 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
US7557183B2 (en) * 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP2007804B1 (en) * 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
BRPI0813139A8 (pt) 2007-06-19 2019-01-29 Glytech Inc peptídeo glp-1 com adição de cadeia oligossacarídea
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
ES2558842T3 (es) * 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
CA2728284C (en) * 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2011088837A1 (en) 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
KR20120123443A (ko) * 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
JP5812627B2 (ja) * 2010-03-10 2015-11-17 公益財団法人相模中央化学研究所 改良Ｆｃ受容体およびその製造方法
KR20130018410A (ko) 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
NZ612297A (en) * 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CA3134906A1 (en) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
HRP20181591T1 (hr) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
TWI601744B (zh) 2011-06-17 2017-10-11 韓美科學股份有限公司 包含調酸素與免疫球蛋白片段之複合物及其用途
JP6184404B2 (ja) * 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
CN103857408B (zh) * 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
ES2602486T3 (es) * 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
MX2014015557A (es) * 2012-06-21 2015-02-24 Univ Indiana Res & Tech Corp Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
SI2864350T1 (en) * 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EA039082B1 (ru) 2012-11-06 2021-12-01 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EP2922877B1 (en) 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
HUE035803T2 (en) * 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
US20160058881A1 (en) * 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
KR102291020B1 (ko) 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
TW201718629A (zh) 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
US20180360973A1 (en) 2015-12-02 2018-12-20 Hanmi Pharm. Co., Ltd. Protein conjugate using a fatty acid derivative and method for preparation thereof
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体

Also Published As

Publication number Publication date
EP3398961A4 (en) 2019-06-12
IL260310B2 (en) 2024-02-01
MX2018008027A (es) 2018-11-29
AU2016382394A1 (en) 2018-08-02
AU2019203891A1 (en) 2019-06-20
EP3398961A1 (en) 2018-11-07
TN2018000228A1 (en) 2019-10-04
PH12018501411A1 (en) 2019-04-08
SG11201805586SA (en) 2018-07-30
UA130717C2 (uk) 2026-04-29
RS63541B1 (sr) 2022-09-30
AU2019203888A1 (en) 2019-06-20
CL2018001795A1 (es) 2018-08-10
CO2018006986A2 (es) 2018-07-10
CN116063453A (zh) 2023-05-05
ZA201804998B (en) 2019-05-29
EP3398961B1 (en) 2022-06-29
IL260318A (en) 2018-08-30
ES2925098T3 (es) 2022-10-13
EP3398962A4 (en) 2019-08-07
IL260318B1 (en) 2023-10-01
PT3398961T (pt) 2022-09-05
KR20200095436A (ko) 2020-08-10
US11332508B2 (en) 2022-05-17
US20190153060A1 (en) 2019-05-23
HK1255834A1 (en) 2019-08-30
WO2017116205A1 (ko) 2017-07-06
EA038524B1 (ru) 2021-09-09
US10370426B2 (en) 2019-08-06
HRP20220995T1 (hr) 2022-11-11
AU2016382393B2 (en) 2019-07-04
BR112018013530A2 (pt) 2018-12-04
AU2016382394B2 (en) 2019-07-04
KR20170080521A (ko) 2017-07-10
HK1258177A1 (en) 2019-11-08
PH12018501411B1 (en) 2024-02-23
JP6712322B2 (ja) 2020-06-17
CL2020002033A1 (es) 2020-10-09
PL3398961T3 (pl) 2022-09-26
KR20190105542A (ko) 2019-09-17
KR20190104958A (ko) 2019-09-11
TWI800478B (zh) 2023-05-01
KR102401869B1 (ko) 2022-05-25
EP3398962A1 (en) 2018-11-07
ECSP18053055A (es) 2018-07-31
CO2018006982A2 (es) 2018-07-10
EP3985017A1 (en) 2022-04-20
SA518391903B1 (ar) 2022-08-01
PH12018501409B1 (en) 2023-03-10
PE20181494A1 (es) 2018-09-18
ZA201804997B (en) 2019-05-29
KR20190062344A (ko) 2019-06-05
JP2019504055A (ja) 2019-02-14
CN108699125B (zh) 2022-10-28
SG11201805573RA (en) 2018-07-30
MX2018008128A (es) 2018-12-06
IL260310B1 (en) 2023-10-01
CR20180380A (es) 2018-12-07
TW201737945A (zh) 2017-11-01
US20190002520A1 (en) 2019-01-03
CN116063454A (zh) 2023-05-05
US20180311315A1 (en) 2018-11-01
NZ744306A (en) 2024-05-31
CN109071624B (zh) 2023-01-17
CN109071624A (zh) 2018-12-21
AU2019203891B2 (en) 2021-05-13
EA201891359A1 (ru) 2019-01-31
WO2017116204A1 (ko) 2017-07-06
TWI877582B (zh) 2025-03-21
EA038544B1 (ru) 2021-09-13
JP2022130723A (ja) 2022-09-06
BR112018013525A2 (pt) 2018-12-04
IL260318B2 (en) 2024-02-01
EA201891360A1 (ru) 2018-12-28
JP2020128428A (ja) 2020-08-27
CL2022000557A1 (es) 2022-09-23
CN115920077B (zh) 2025-07-04
PH12018501409A1 (en) 2019-04-08
CL2018001776A1 (es) 2018-08-10
CN116059389A (zh) 2023-05-05
DK3398961T3 (da) 2022-08-22
PE20181574A1 (es) 2018-10-03
ECSP18053053A (es) 2018-07-31
US20220213164A1 (en) 2022-07-07
KR20200096184A (ko) 2020-08-11
KR102367997B1 (ko) 2022-03-02
CL2022000558A1 (es) 2022-09-23
KR102179391B1 (ko) 2020-11-16
JP7030894B2 (ja) 2022-03-07
KR102179392B1 (ko) 2020-11-16
TWI731015B (zh) 2021-06-21
CL2020002034A1 (es) 2020-10-09
PE20250556A1 (es) 2025-02-24
JP7526039B2 (ja) 2024-07-31
KR102285377B1 (ko) 2021-08-04
AU2019203888B2 (en) 2021-05-13
NZ744321A (en) 2024-04-26
TWI807580B (zh) 2023-07-01
TW202216748A (zh) 2022-05-01
IL260310A (en) 2018-08-30
UA130791C2 (uk) 2026-05-20
CA3010265C (en) 2025-05-20
US10981967B2 (en) 2021-04-20
JP6712323B2 (ja) 2020-06-17
CA3010265A1 (en) 2017-07-06
TW202330585A (zh) 2023-08-01
CN115920077A (zh) 2023-04-07
AU2016382393A1 (en) 2018-08-02
TN2018000231A1 (en) 2019-10-04
CN116063454B (zh) 2026-06-05
JP2019504057A (ja) 2019-02-14
JP2020171287A (ja) 2020-10-22
TW201730207A (zh) 2017-09-01
HUE059737T2 (hu) 2022-12-28
US20190218269A1 (en) 2019-07-18
KR20170080522A (ko) 2017-07-10
US20210188937A1 (en) 2021-06-24
CR20180381A (es) 2019-01-14
DOP2018000159A (es) 2018-09-30
SA518391891B1 (ar) 2021-07-12
KR102285378B1 (ko) 2021-08-04
CA3010182A1 (en) 2017-07-06
US10400020B2 (en) 2019-09-03
CN108699125A (zh) 2018-10-23
KR20190060749A (ko) 2019-06-03

Similar Documents

Publication Publication Date Title
ECSP18053055A (es) Agonista triple de receptores de glucagón/glp-1/gip
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
EP3359445A4 (en) GEOSTATIONARY HEIGHT PLATFORM
CL2015002738A1 (es) Xantinas sustituidas y métodos de uso de las mismas.
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
CR20180564A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
MX2020003217A (es) Coagonistas de accion prolongada de los receptores de glucagon y glp-1.
MX2018003269A (es) Representacion de datos de campo de luz.
DK3347360T3 (da) Forbindelser, som er anvendelige til inhibering af ror-gamma-t
DOP2017000264A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
BR112018067344A2 (pt) liraglutida em condições cardiovasculares
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MY199261A (en) Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
MX385250B (es) Jabones antimicrobianos que contienen carvacrol y metodos de uso de los mismos.
ES1212091Y (es) Composición que comprende resina para su uso como relicario.
CR20150533A (es) Compuesto peptídico